Cell & Gene by Oxford Global’s Post

While discoveries involving the various AAV serotypes for gene therapies are exciting, their distinct biological properties require tailored, stage-appropriate analytical methods. Can serotype-agnostic platforms help us keep pace with the ever-increasing speed of process development activities? Tune into our on-demand webinar with experts from Resilience & Lacerta Therapeutics to discover their methods. Watch now: https://hubs.ly/Q01Yqvrg0 #GeneTherapy #Webinar #AnalyticalDevelopment #ProcessDevelopment #Manufacturing #Innovation

Interesting discussion at Meeting on the Med with investors and analysts not only talking about investment trends but also the importance of ensuring ethical access to life changing cell and gene therapies in low and middle income countries. Bo Wiinberg and Sven Kili debating ideas how to drive better access faster through lower cost of goods. #meetingonthemed #ethicalbiotech #cgt #advancedtherapies

Protein and Cell & Gene Scientists! How tightly are you verifying sample suitability for downstream applications? Screen samples without labels, immobilization, or fluorescence tagging an get results in 5 minutes or less. Join us at Booth #559 to explore how mass photometry can work for you. Let's chart the future of protein science together! #GenomePackaging #Proteins #AAV #BPI2023

Did you know? Our study is recruiting patients w/ #ATP1A3 gene variants: https://buff.ly/3EN20Wz We aim to better identify characteristics associated w/ #RDP, #AHC & #CAPOS. We also aim to explore whether variants in the ATP1A3 gene are linked w/ dystonias & #ParkinsonsDisease.

Struggling with repeat sequences affecting your research? Discover the power of codon optimization in streamlining gene transcription and enhancing protein expression! Our complimentary codon optimization tool is your solution for maximum synthetic performance. Dive into the details here: https://hubs.ly/Q024TX4t0 #CodonOptimization #ProteinExpression #ResearchEnhancement

Accelerate your gene function research with OriGene’s Lentiviral Products! 🚀 Efficiently knock down or overexpress genes with Lenti shRNA and Lenti-ORF options. Perfect for a variety of cell types. Click Here to Learn More: https://hubs.ly/Q02JDGmf0

Barriers to patient access vary widely by area. For example, cell and gene therapies are limited by restrictive PA criteria, inadequate reimbursement, site-level capacity challenges and referral gaps. See the four key points from our #MarketAccess research in this blog: https://ow.ly/4QOW50RZ2BA

Did you know? Our study is recruiting patients w/ #ATP1A3 gene variants: https://buff.ly/3EN20Wz We aim to better identify characteristics associated w/ #RDP, #AHC & #CAPOS. We also aim to explore whether variants in the ATP1A3 gene are linked w/ dystonias & #ParkinsonsDisease.

Did you know you can search #PubChem RDF subdomains (such as author, cell line, gene, protein, and more) using a RESTful interface? Find out more details: https://ow.ly/HLfq50SfF6E

Gene therapies have come a long way but the availability of popular delivery systems, such as AAV vector, limit their availability for patients.   🎥 In our latest edition of the #HowDoesItWork series, we explore TESSA Vectors. Curious to learn more? Watch below.   Follow along each week or subscribe to our YouTube channel: https://lnkd.in/gFhuuPDP    #STEM #GeneTherapy #Innovation #Biotechnology